GlassScriptPhysician profile
Anibal J Maldonado
NPI 1326120924
$2,557.94
in general payments reported to CMS, 2019-2025
18 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $160 · 2021: $29.83 · 2022: $195 · 2023: $333 · 2024: $937 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $456.86 | 2019-2025 | Arikayce |
| Tetraphase Pharmaceuticals, INC. | $259.66 | 2019-2025 | |
| Shionogi INC | $233.55 | 2023-2025 | Fetroja |
| Melinta Therapeutics, LLC | $225.08 | 2021-2025 | Kimyrsa, Rezzayo, Vabomere |
| Paratek Pharmaceuticals, INC. | $190.13 | 2022-2025 | Nuzyra |
| Allergan, INC. | $158.25 | 2019 | |
| Smith+Nephew, INC. | $151.27 | 2024 | Grafix Pl, Collagenase Santyl |
| Janssen Biotech, INC. | $150.47 | 2019 | |
| Mimedx Group, INC. | $139.70 | 2024 | |
| Merck Sharp & Dohme LLC | $136.39 | 2020-2024 | Dificid, Zerbaxa, Recarbrio |
| La Jolla Pharmaceutical Company | $123.76 | 2023-2024 | Xerava |
| Organogenesis INC. | $103.23 | 2024 | |
| Astellas Pharma US INC | $97.24 | 2024-2025 | Cresemba |
| Abbvie INC. | $47.17 | 2024-2025 | |
| Cumberland Pharmaceuticals, INC. | $26.81 | 2023-2024 | Vibativ |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $22.64 | 2021-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Integra Lifesciences Corporation | $18.71 | 2025 | Tcc-Ez |
| Urgo Medical North America, LLC | $17.02 | 2024 | Urgok2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anibal Maldonado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.